Setback for Bristol Myers Squibb: CheckMate -73L trial fails to meet endpoint
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -73L trial did not achieve its primary endpoint of progression-free survival (PFS) in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). This clinical trial evaluated the efficacy of Opdivo (nivolumab) combined with concurrent chemoradiotherapy (CCRT), followed by Opdivo plus Yervoy […]